news12 January 2021 | By Hannah Balfour (European Pharmaceutical Review)
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).